Get started
Author

Ibolya Laczó

Observed names: IBOLYA LACZÓ, Ibolya Laczo, Laczó Ibolya
Observed institution: Békés Megyei Központi Kórház
ORCID: 0000-0002-6371-7661
Observed ORCID: 0000-0002-6371-7661
OpenAlex ID: A5018405275
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
2019 · Tony S K Mok, Yi-Long Wu, et al. · The Lancet · 3,479
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,452
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 740
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
2025 · Jeffrey D. Bradley, Shunichi Sugawara, et al. · Journal of Clinical Oncology · 97
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer
2024 · David R. Spigel, Afshin Dowlati, et al. · Journal of Clinical Oncology · 49
The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract
2018 · BOGLÁRKA PÓSFAI, LEVENTE KUTHI, et al. · Anticancer Research · 28
PDF
Overview of extravasation management and possibilities for risk reduction based on literature data
2013 · Béla Pikó, Ibolya Laczó, et al. · Journal of Nursing Education and Practice · 11
PDF
ERG expression can predict the outcome of docetaxel combinedwith androgen deprivation therapy in metastatic hormone-sensitiveprostate cancer
2019 · Zsófia Küronya, Farkas Sükösd, et al. · Urologic Oncology Seminars and Original Investigations · 9
Glycoproteomics Analysis of Triple Wild-Type Lung Adenocarcinoma Tissue Samples
2025 · Simon Nándor Sugár, Balázs András Molnár, et al. · Journal of Proteome Research · 4
PDF
Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK , EGFR , and KRAS genetic alterations
2025 · Fanni Bugyi, Mirjam Balbisi, et al. · Molecular Oncology
PDF
A Rare but Real Entity: Bladder Neuroendocrine Cancer
2022 · Béla Pikó, Ali Bassam, et al. · IntechOpen eBooks
PDF
[Rare, but existing clinical entity - the neuroendocrine cancer of the bladder].
2021 · Béla Pikó, Anita Kis, et al. · PubMed
Darolutamid: új szer a nem metasztatikus, kasztrációrezisztens prosztatarák kezelésében
2021 · Béla Pikó, Ali Bassam, et al. · Magyar urológia
Radiochemotherapy - questions/answers
2017 · Béla Pikó, Laczó Ibolya
[Fulvestrant (Faslodex®) for hormone sensitive breast cancer. A review].
2015 · Tamás Nagykálnai, László Landherr, et al. · PubMed
Fulvestrant and long progression free survival: a patient with metastatic breast cancer
2014 · Bánhegyi Róbert János, Laczó Ibolya, et al. · Lege Artis Medicinae
Works count: 17
Citation count: 6,869
H-index: 8
I10-index: 7
Year
Topic
Type